Impact of a pharmacist-driven tardive dyskinesia screening service
Introduction: Tardive dyskinesia (TD) is defined as involuntary movements that can develop with prolonged antipsychotic use. Regular monitoring using the Abnormal Involuntary Movement Scale (AIMS) is recommended to be conducted every 3 to 6 months for early recognition, although the AIMS is underuse...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
American Association of Psychiatric Pharmacists
2021-07-01
|
| Series: | Mental Health Clinician |
| Subjects: | |
| Online Access: | https://theijpt.org/doi/pdf/10.9740/mhc.2021.07.248 |
| _version_ | 1797383390858575872 |
|---|---|
| author | Niyati Butala, PharmD, BCPP Andrew Williams, PharmD, BCPP, BCGP Jamie Kneebusch, PharmD, BCPS, BCPP Melissa Mitchell, PharmD, BCPS, BCPP, BCGP |
| author_facet | Niyati Butala, PharmD, BCPP Andrew Williams, PharmD, BCPP, BCGP Jamie Kneebusch, PharmD, BCPS, BCPP Melissa Mitchell, PharmD, BCPS, BCPP, BCGP |
| author_sort | Niyati Butala, PharmD, BCPP |
| collection | DOAJ |
| description | Introduction: Tardive dyskinesia (TD) is defined as involuntary movements that can develop with prolonged antipsychotic use. Regular monitoring using the Abnormal Involuntary Movement Scale (AIMS) is recommended to be conducted every 3 to 6 months for early recognition, although the AIMS is underused. Several studies have investigated risk factors that may be associated with TD, including age, sex, and long-term antipsychotic use. This study aimed to increase the monitoring and treatment of TD for those assessed to be at higher risk.
Methods: This was a prospective quality improvement study on the effectiveness of a psychiatric pharmacist–driven TD screening service (PPDTSS) in an inpatient psychiatric facility. Participants were composed of adult patients admitted between May and November 2018. Patients were screened daily by a clinical pharmacist and, if determined to be high risk based on studied risk factors, prioritized to receive a formal TD screening via the AIMS. The primary objective was to optimize standard of care by increasing the number of AIMS screenings conducted. The secondary objective was to increase the treatment of TD.
Results: A total of 402 patients were assessed prior to implementation of the PPDTSS, and 390 patients were screened following implementation. The PPDTSS increased the number of AIMS screenings attempted by 85.1% for high-risk individuals. Of the 75 patients who had an AIMS screening attempted in the postintervention group, 46 (61.3%) had an AIMS screening completed, of which 3 (6.5%) were positive.
Discussion: The results of this study demonstrate that psychiatric pharmacists can be used to improve the regular monitoring of patients at high risk for TD. |
| first_indexed | 2024-03-08T21:20:15Z |
| format | Article |
| id | doaj.art-554d189519774343832a33f1b38bbcf7 |
| institution | Directory Open Access Journal |
| issn | 2168-9709 |
| language | English |
| last_indexed | 2024-03-08T21:20:15Z |
| publishDate | 2021-07-01 |
| publisher | American Association of Psychiatric Pharmacists |
| record_format | Article |
| series | Mental Health Clinician |
| spelling | doaj.art-554d189519774343832a33f1b38bbcf72023-12-21T11:42:19ZengAmerican Association of Psychiatric PharmacistsMental Health Clinician2168-97092021-07-0111424825310.9740/mhc.2021.07.248i2168-9709-11-4-248Impact of a pharmacist-driven tardive dyskinesia screening serviceNiyati Butala, PharmD, BCPP0https://orcid.org/0000-0003-0383-6068Andrew Williams, PharmD, BCPP, BCGP1https://orcid.org/0000-0003-3140-414XJamie Kneebusch, PharmD, BCPS, BCPP2https://orcid.org/0000-0001-6721-6381Melissa Mitchell, PharmD, BCPS, BCPP, BCGP3https://orcid.org/0000-0002-1875-75411 Clinical Pharmacist, Riverside University Health System, Riverside, California2 Senior Clinical Pharmacist, Riverside University Health System, Riverside, California3 Clinical Pharmacist, Riverside University Health System, Riverside, California4 Senior Clinical Pharmacist–Special Projects, Riverside University Health System, Riverside, CaliforniaIntroduction: Tardive dyskinesia (TD) is defined as involuntary movements that can develop with prolonged antipsychotic use. Regular monitoring using the Abnormal Involuntary Movement Scale (AIMS) is recommended to be conducted every 3 to 6 months for early recognition, although the AIMS is underused. Several studies have investigated risk factors that may be associated with TD, including age, sex, and long-term antipsychotic use. This study aimed to increase the monitoring and treatment of TD for those assessed to be at higher risk. Methods: This was a prospective quality improvement study on the effectiveness of a psychiatric pharmacist–driven TD screening service (PPDTSS) in an inpatient psychiatric facility. Participants were composed of adult patients admitted between May and November 2018. Patients were screened daily by a clinical pharmacist and, if determined to be high risk based on studied risk factors, prioritized to receive a formal TD screening via the AIMS. The primary objective was to optimize standard of care by increasing the number of AIMS screenings conducted. The secondary objective was to increase the treatment of TD. Results: A total of 402 patients were assessed prior to implementation of the PPDTSS, and 390 patients were screened following implementation. The PPDTSS increased the number of AIMS screenings attempted by 85.1% for high-risk individuals. Of the 75 patients who had an AIMS screening attempted in the postintervention group, 46 (61.3%) had an AIMS screening completed, of which 3 (6.5%) were positive. Discussion: The results of this study demonstrate that psychiatric pharmacists can be used to improve the regular monitoring of patients at high risk for TD.https://theijpt.org/doi/pdf/10.9740/mhc.2021.07.248tardive dyskinesiatdaimsscreening toolpharmacisteps |
| spellingShingle | Niyati Butala, PharmD, BCPP Andrew Williams, PharmD, BCPP, BCGP Jamie Kneebusch, PharmD, BCPS, BCPP Melissa Mitchell, PharmD, BCPS, BCPP, BCGP Impact of a pharmacist-driven tardive dyskinesia screening service Mental Health Clinician tardive dyskinesia td aims screening tool pharmacist eps |
| title | Impact of a pharmacist-driven tardive dyskinesia screening service |
| title_full | Impact of a pharmacist-driven tardive dyskinesia screening service |
| title_fullStr | Impact of a pharmacist-driven tardive dyskinesia screening service |
| title_full_unstemmed | Impact of a pharmacist-driven tardive dyskinesia screening service |
| title_short | Impact of a pharmacist-driven tardive dyskinesia screening service |
| title_sort | impact of a pharmacist driven tardive dyskinesia screening service |
| topic | tardive dyskinesia td aims screening tool pharmacist eps |
| url | https://theijpt.org/doi/pdf/10.9740/mhc.2021.07.248 |
| work_keys_str_mv | AT niyatibutalapharmdbcpp impactofapharmacistdriventardivedyskinesiascreeningservice AT andrewwilliamspharmdbcppbcgp impactofapharmacistdriventardivedyskinesiascreeningservice AT jamiekneebuschpharmdbcpsbcpp impactofapharmacistdriventardivedyskinesiascreeningservice AT melissamitchellpharmdbcpsbcppbcgp impactofapharmacistdriventardivedyskinesiascreeningservice |